<DOC>
	<DOC>NCT01947816</DOC>
	<brief_summary>This investigation will be conducted to obtain the following information regarding the use of Humira 40mg Syringe 0.8mL for Subcutaneous Injection in patients with Ulcerative Colitis. 1. Unknown adverse reactions (in particular, clinically significant) 2. Incidence and conditions of occurrence of adverse reactions in clinical practice 3. Factors likely to affect the safety and effectiveness</brief_summary>
	<brief_title>Special Investigation in Patients With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Patients receiving Humira for the first time for the treatment of Ulcerative Colitis Contraindications according to the Package Insert include patients who have any of the following: serious infections tuberculosis a history of hypersensitivity to any ingredient of Humira demyelinating disease or a history of demyelinating disease congestive cardiac failure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ulcerative Colitis</keyword>
</DOC>